Sun Pharma (SUNPHARMA) Financial Ratio Screen
Follow screening changes
Email alerts are not currently available. Bookmark this page and check the financial period and retrieval date when reviewing a result.
MSCI new-inclusion financial-ratio snapshot
SUNPHARMA financial screening at a glance
Calculation date: 2026-10-15. Financial period used: March 2026. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.
Independent method comparison
What the available screens say
How MSCI, FTSE and S&P-style screens differThe request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.
Business activity evidence
Activity assessment in progress
The supplied classification (Drug Manufacturers - Specialty & Generic) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.
Revenue segments: Not yet checked against an SEC annual filing.
Profile description reviewed: Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; specialty medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers generics and APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.
Sources to verify: Secondary company profile and classification · Issuer website
A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.
Published-ratio reproductions (not certifications)
The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style debt and cash reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.
Based on financial data from March 2026
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| MSCI | 4.3% / 30% | 31.1% / 30% | 23.2% / 30% | 1.57% / 5% | RATIOS FAIL* |
| FTSE | 4.3% / 33% | 31.1% / 33% | 23.2% / 50% | 1.57% / 5% | FINANCIAL SCREEN PASSED* |
Financial Highlights
Profitability
| Gross Margin | 78.9% | |
| Operating Margin | 23.2% | |
| Net Margin | 20.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | INR 124.2B |
| Free Cash Flow | INR 88.1B |
| Total Debt | INR 46.3B |
| Debt-to-Equity | 5.5 |
| Total Assets | INR 1.1T |
Price & Trading
| Last Close | INR 1,759.80 |
| 50-Day MA | INR 1,884.87 |
| 200-Day MA | INR 1,808.76 |
| Avg Volume | 1.9M |
| Beta | 0.1 |
|
52-Week Range
INR 1,583.70
| |
Financial data provenance and verification
The displayed fields were imported from yfinance on 2026-10-10 for the financial period March 2026. This is a secondary data feed and can differ from amended or newly filed statements.
- Issuer website — use its investor-relations filings to verify the figures.
- Field mapping, formulas and limitations.
Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.
About Sun Pharma (SUNPHARMA)
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; specialty medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers generics and APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.
Popular halal stock checks
Explore other frequently viewed automated stock screens and compare the available financial ratios.
Frequently Asked Questions
Is Sun Pharma (SUNPHARMA) halal to invest in?
The current automated result is Financial criteria not met or an activity exclusion was detected. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.
What is Sun Pharma's debt ratio?
Sun Pharma's debt ratio is 4.3% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.
What are Sun Pharma's key financial metrics?
Sun Pharma has a market capitalization of INR 4222829M in its listing currency, trailing P/E ratio of 34.9, and revenue of INR 582.2B. The company maintains a gross margin of 78.9% and a net margin of 20.2%.
How often is the screening data updated?
Calculation date: 2026-10-15. Financial period: March 2026. These dates are shown separately because regenerating this page does not refresh the underlying data.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.